TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 6nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 7nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 8nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 9nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 12nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 13nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 15nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 17nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair
TargetPoly [ADP-ribose] polymerase 1(Homo sapiens (Human))
Chengdu Di'Ao Pharmaceutical Group
US Patent
Chengdu Di'Ao Pharmaceutical Group
US Patent
Affinity DataIC50: 30nMT: 2°CAssay Description:PARP-1 can catalyze the NAD-dependent addition of poly (ADP-ribose) to adjacent nuclear proteins such as histone. The activity of PARP was determined...More data for this Ligand-Target Pair